Clinical trials: Pneumonia
COVID-19 Infection
"CHANGE COVID-19 Severity"
We are conducting an investigator-initiated, single center, blinded, placebo-controlled, randomized clinical trial evaluating magnesium citrate combined with a probiotic for the treatment of adults hospitalized with COVID-19.
- Trial name
- CHANGE (NCT04941703)
- Testing
- Magnesium Citrate plus probiotic
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Vanderbilt University Medical Center
COVID-19, SARS-CoV-2 Infection
COVID-19 Observational Research Collaboratory
This study aims to examine the long-term outcomes in Veterans infected and uninfected with SARS-CoV-2 using electronic health record information and structured surveys.
- Trial name
- CORC LTO (NCT05394025)
- Where
- 6 sites in United States
- Volunteers
- 479 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Chronic Spontaneous Urticaria
A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients
A safety extension study to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria (CSU) patients who completed study CQGE031C2201
- Trial name
- NCT02649218
- Testing
- Ligelizumab
- Where
- 67 sites in United States, Australia and 8 more
- Volunteers
- 226 people
- Sponsor
- Novartis Pharmaceuticals
Pneumonia
A Study of Auxora in Patients With Critical COVID-19 Pneumonia
This is a single-blind study of Auxora in patients with critical COVID-19 pneumonia, consisting of up to 3 cohorts of escalating dose.
- Trial name
- NCT04661540
- Testing
- CM4620-IE (Injectable Emulsion)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- CalciMedica, Inc.
COVID-19, COVID
Pegylated Interferon Lambda Treatment for COVID-19
Prospective randomized trial to assess the antiviral efficacy of Pegylated Interferon Lambda (180 mcg SC injection) vs.placebo in up to 20 subjects with COVID-19 infection.
- Trial name
- NCT04343976
- Testing
- Pegylated interferon lambda
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Raymond Chung
Chronic Graft Versus Host Disease
Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
This pilot clinical trial studies how well vismodegib works in treating patients with chronic graft-versus-host disease that did not respond to previous steroid treatment.
- Trial name
- NCT02337517
- Testing
- Laboratory Biomarker Analysis, Vismodegib
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Influenza,Human, COVID-19
A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People
This study is to learn about flu and COVID vaccines, either alone or when mixed together. Healthy people aged 18 or older can join. Participants will get one shot in each arm, either a flu or COVID vaccine, alone or mixed.
- Trial name
- NCT06683352
- Testing
- Investigational Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza/COVID-19 Vaccine
- Where
- 22 sites in United States
- Volunteers
- 1,353 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19
Non-comparative Trial of the Combination of HCQ and AZI in the Treatment of ICU Patients
This research is designed as an open-label,non-comparative prospective trial.
- Trial name
- NCT04458948
- Testing
- Hydroxychloroquine, Azithromycin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of New Mexico
Coronavirus Infection, Covid-19
Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19
This pilot study is being performed to assess the efficacy and safety of inhaled ensifentrine delivered via pMDI compared with a matching placebo in conjunction with standard of care treatments on recovery in patients…
- Conditions
- Coronavirus Infection, Covid-19, SARS-CoV-2
- Trial name
- NCT04527471
- Testing
- Ensifentrine Dose 1
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Verona Pharma Inc
Psoriasis, Skin Diseases
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index…
- Conditions
- Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
- Trial name
- NCT01490632
- Testing
- Baricitinib
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 271 people
- Sponsor
- Eli Lilly and Company
Immunocompromised
A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults
The primary objective of the study is to evaluate the effect of casirivimab+imdevimab, compared with placebo, in preventing symptomatic SARS-CoV-2 infection in immunocompromised participants.
- Trial name
- NCT05074433
- Testing
- casirivimab+imdevimab
- Where
- 67 sites in United States, Mexico
- Volunteers
- 66 people
- Sponsor
- Regeneron Pharmaceuticals
COVID-19
Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19
To determine the effect of favipiravir + SOC v. SOC on COVID-19 viral clearance.
- Trial name
- NCT04358549
- Testing
- Favipiravir, Standard of Care
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
COVID-19
Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
In this study, the investigators propose to administer clazakizumab to patients with life-threatening Coronavirus Disease 2019 (COVID-19) infection manifest by pulmonary failure and a clinical picture consistent with a cytokine…
- Trial name
- NCT04381052
- Testing
- Clazakizumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Columbia University
Chronic Graft Versus Host Disease
Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD
Chronic graft versus host diseasre (GVHD) is a serious reaction that might occur in a person (the host) who has received cells or organs (graft) from another person because the graft attacks the host's cells.
- Trial name
- NCT02461134
- Testing
- Ponesimod
- Volunteers
- 1 people
- Sponsor
- Actelion
Pseudomonas Aeruginosa Pneumonia
Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia
Prospective, double-blind, randomized assessment of the efficacy, safety and pharmacokinetic of Aerucin® as adjunct treatment (in addition to standard of care antibiotics) for pneumonia caused by P. aeruginosa.
- Trial name
- NCT03027609
- Testing
- AR-105
- Where
- 111 sites in United States, Australia and 15 more
- Volunteers
- 158 people
- Sponsor
- Aridis Pharmaceuticals, Inc.
COVID-19, Sars-CoV2
Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients
The purpose of this study assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms up to 14 days after the onset of initial symptoms.
- Trial name
- CAPRI (NCT04421404)
- Testing
- COVID-19 Convalescent Plasma (CCP)
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Priscilla Hsue, MD
COVID-19
Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19
Tocilizumab is an effective treatment for severe coronavirus disease 2019 (Covid-19) pneumonia and related inflammation. Given limited global supplies, clarification of the optimal tocilizumab dose is critical.
- Trial name
- COVIDOSE-2 (NCT04479358)
- Testing
- Tocilizumab, Standard of Care
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- University of Chicago
SARS-CoV 2, COVID-19
Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers
The purpose of this study is to identify healthcare workers with SARS CoV 2 antibodies who have not been previously diagnosed and are presumed COVID-19 negative, then determine the level of immunity in this population which could…
- Trial name
- NCT04383587
- Testing
- Serologic testing
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
SARS-CoV-2, COVID-19 Vaccines
Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data
The primary purpose of this study is to learn about how well different versions of the Pfizer-BioNTech COVID-19 vaccine (called BNT162b2) work at preventing death, severe COVID-19 that requires a trip to the hospital, and overall…
- Trial name
- NCT06199934
- Testing
- Vaccination
- Where
- United States
- Volunteers
- 19,853,610 people
- Sponsor
- Pfizer
Asthma
Asthma in Families Facing Out-of-pocket Requirements Due to COVID-19
In addition to its impact on health, the COVID-19 pandemic led to increased unemployment and loss of employer-sponsored insurance coverage.
- Trial name
- AFFORD COVID (NCT04613739)
- Testing
- insurance navigation
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Harvard Pilgrim Health Care
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.